Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
23 October 2024 - 11:00PM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that
Jeffrey A. Meckler, Chief Executive Officer, will present at two
upcoming investor conferences:
BioFuture 2024
The conference is being held on October 28 – 30,
2024 at Cure by Deerfield in New York City.
Presentation Date: |
Monday,
October 28, 2024 |
Time: |
3:30 PM ET |
Track: |
12 - B (12th Floor) |
Mr. Meckler will be available for one-on-one
meetings throughout the conference.
For more information about BioFuture, click
here: https://biofuture.com/
ThinkEquity Conference
The conference is being held on October 30, 2024
at the Mandarin Oriental Hotel in New York City.
Presentation Date: |
Wednesday,
October 30, 2024 |
Time: |
12:30 PM ET (South Salon II) |
Mr. Meckler will be available for one-on-one meetings throughout
the conference.
Interested investors can register to attend and schedule
one-on-one meetings here.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company’s novel approach
is based on the hypothesis that efficient activation of both innate
and adaptive immune cells and pathways and associated anti-tumor
and anti-viral immune responses will require a multi-targeted
package of immune system-activating signals that can be
administered safely intravenously (i.v.). Indaptus’ patented
technology is composed of single strains of attenuated and killed,
non-pathogenic, Gram-negative bacteria producing a multiple
Toll-like receptor (TLR), Nucleotide oligomerization domain
(NOD)-like receptor (NLR) and Stimulator of interferon genes
(STING) agonist Decoy platform. The product candidates are designed
to have reduced i.v. toxicity, but largely uncompromised ability to
prime or activate many of the cells and pathways of innate and
adaptive immunity. Decoy product candidates represent an
antigen-agnostic technology that have produced single-agent
activity against metastatic pancreatic and orthotopic colorectal
carcinomas, single agent eradication of established
antigen-expressing breast carcinoma, as well as
combination-mediated eradication of established hepatocellular
carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard
pre-clinical models, including syngeneic mouse tumors and human
tumor xenografts. In pre-clinical studies tumor eradication was
observed with Decoy product candidates in combination with
anti-PD-1 checkpoint therapy, low-dose chemotherapy, a
non-steroidal anti-inflammatory drug, or an approved, targeted
antibody. Combination-based tumor eradication in pre-clinical
models produced innate and adaptive immunological memory, involved
activation of both innate and adaptive immune cells, and was
associated with induction of innate and adaptive immune pathways in
tumors after only one i.v. dose of Decoy product candidate, with
associated “cold” to “hot” tumor inflammation signature transition.
IND-enabling, nonclinical toxicology studies demonstrated i.v.
administration without sustained induction of hallmark biomarkers
of cytokine release syndromes, possibly due to passive targeting to
liver, spleen, and tumor, followed by rapid elimination of the
product candidate. Indaptus’ Decoy product candidates have also
produced meaningful single agent activity against chronic hepatitis
B virus (HBV) and chronic human immunodeficiency virus (HIV)
infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management’s
expectations, beliefs and intentions regarding, among other things:
our expectations and plans regarding our Phase 1 clinical trial of
Decoy20, including the timing and design thereof and expected
immune responses as we dose more patients in the multi-dosing part
of the trial; the anticipated effects of our product candidates,
including Decoy20; the plans and objectives of management for
future operations; our research and development activities and
costs; the sufficiency of our cash and cash equivalents to fund our
ongoing activities and our cash management strategy; and our
assessment of financing options to support our corporate strategy.
Forward-looking statements can be identified by the use of
forward-looking words such as “believe”, “expect”, “intend”,
“plan”, “may”, “should”, “could”, “might”, “seek”, “target”,
“will”, “project”, “forecast”, “continue” or “anticipate” or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Because forward-looking statements relate to
matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause our actual
results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause
actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to the following: our limited operating
history; conditions and events that raise substantial doubt
regarding our ability to continue as going concern; the need for,
and our ability to raise, additional capital given our lack of
current cash flow; our clinical and preclinical development, which
involves a lengthy and expensive process with an uncertain outcome;
our incurrence of significant research and development expenses and
other operating expenses, which may make it difficult for us to
attain profitability; our pursuit of a limited number of research
programs, product candidates and specific indications and failure
to capitalize on product candidates or indications that may be more
profitable or have a greater likelihood of success; our ability to
obtain and maintain regulatory approval of any product candidate;
the market acceptance of our product candidates; our reliance on
third parties to conduct our preclinical studies and clinical
trials and perform other tasks; our reliance on third parties for
the manufacture of our product candidates during clinical
development; our ability to successfully commercialize Decoy20 or
any future product candidates; our ability to obtain or maintain
coverage and adequate reimbursement for our products; the impact of
legislation and healthcare reform measures on our ability to obtain
marketing approval for and commercialize Decoy20 and any future
product candidates; product candidates of our competitors that may
be approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our Quarterly Report on Form
10-Q for the quarter ended June 30, 2024 filed with the SEC on
August 12, 2024, our most recent Annual Report on Form 10-K filed
with the SEC on March 13, 2024, and our other filings with the SEC,
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. All forward-looking statements speak only as of the date
of this press release and are expressly qualified in their entirety
by the cautionary statements included in this press release. We
undertake no obligation to update or revise forward-looking
statements to reflect events or circumstances that arise after the
date made or to reflect the occurrence of unanticipated events,
except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:CORE IRLouie
Tomalouie@coreir.com
Media Contact:Cuttlefish CommunicationsShira
Derasmoshira@cuttlefishpr.com917-280-2497
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Dec 2023 to Dec 2024